Section 230 platform liability
Section 230 liability exposure is an active pressure point for Healthcare & Life Sciences companies that operate patient-facing platforms, symptom checkers, or provider review tools. The U.S. Federal Trade Commission has signaled scrutiny of health platforms that moderate or amplify user-generated medical content, and the U.S. Department of Health and Human Services Office for Civil Rights has issued guidance tying platform content decisions to HIPAA accountability in specific contexts. Courts are narrowing the immunity window faster than Congress has acted, which means legal teams cannot treat Section 230 as a stable backstop for AI-assisted or algorithmically curated health content.
Watch
- Gonzalez v. Google precedent: how algorithmic curation affects health platform immunity claims
- HHS Office for Civil Rights guidance on user-generated content and HIPAA platform liability
- FTC Act Section 5 enforcement against deceptive health content moderation practices
- State-level platform liability bills in California and Texas with carve-outs for medical misinformation
- Congressional HEALTH ONLINE Act proposals that would strip Section 230 from symptom-checker outputs
Recent material activity in Healthcare & Life Sciences
-
FDA issues Complete Response Letter for novel GLP-1 receptor agonist oral formulation
The FDA issued a CRL for a once-daily oral GLP-1 receptor agonist citing manufacturing consistency concerns at the primary production facility. The agency requested additional CMC data and a pre-approval inspection befor…
Read a full sample brief →